Functional mannose-binding lectin haplotype variants are associated with alzheimer's disease

Journal of Alzheimer's Disease

Volumn 35, Issue 1, 2013, Pages 121-127

  Sjölander, Annica ^a   Minthon, Lennart ^b   Nuytinck, Lieve ^c   Vanmechelen, Eugeen ^d   Blennow, Kaj ^a   Nilsson, Staffan ^e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c GHENT UNIVERSITY   (Belgium)

^d Key4AD   (Belgium)

^e CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Alzheimer's disease; cerebrospinal fluid; gene; immune response; Mannan Binding lectin; single nucleotide polymorphism

Indexed keywords

MANNOSE BINDING LECTIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84876352131     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122044     Document Type: Article

References (27)

1. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Ruther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O'Donovan MC, Owen MJ, Williams J (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 5, e13950.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
3. Schenk D, Hagen M, Seubert P (2004) Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16, 599-606. (Pubitemid 39165888)
4. Boche D, Nicoll JA, Weller RO (2005) Immunotherapy for Alzheimer's disease and other dementias. Curr Opin Neurol 18, 720-725. (Pubitemid 41669147)
5. Cummings JL, Doody R, Clark C (2007) Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 69, 1622-1634. (Pubitemid 350287147)
6. Lanzrein AS, Jobst KA, Thiel S, Jensenius JC, Sim RB, Perry VH, Sim E (1998) Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease. Neuroreport 9, 1491-1495. (Pubitemid 28264276)
7. McGeer PL, Rogers J, McGeer EG (1994) Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 8, 149-158. (Pubitemid 24282544)
8. Heitzeneder S, Seidel M, Forster-Waldl E, Heitger A (2012) Mannan-binding lectin deficiency - Good news, bad news, doesn't matter? Clin Immunol 143, 22-38.
9. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO (2006) Mannose-binding lectin and its genetic variants. Genes Immun 7, 85-94. (Pubitemid 43336050)
10. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A (1995) Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 155, 3013-3020.
11. Boldt AB, Petzl-ErlerML(2002)Anewstrategy for mannosebinding lectin gene haplotyping. Hum Mutat 19, 296-306. (Pubitemid 34195192)
12. Antonarakis SE (1998) Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 11, 1-3. (Pubitemid 128679142)
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
14. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
15. Nuytinck L, De Meester E, Van Thielen M, Govaerts P (2006) Role of mannose-binding lectin (MBL2) genotyping in predicting the risk of recurrent otitis media (rOM). Adv Exp Med Biol 586, 281-290.
16. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24, 87-97. (Pubitemid 34066679)
17. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680. (Pubitemid 29266465)
18. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245. (Pubitemid 26002016)
19. Braak E, Braak H, Mandelkow EM (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87, 554-567. (Pubitemid 24158408)
20. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
21. ClarkAG(1990) Inference of haplotypes from PCR-amplified samples of diploid populations. Mol Biol Evol 7, 111-122.
22. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379. (Pubitemid 32217453)
23. Naito H, Ikeda A, Hasegawa K, Oka S, Uemura K, Kawasaki N, Kawasaki T (1999) Characterization of human serum mannan-binding protein promoter. J Biochem 126, 1004-1012. (Pubitemid 30014445)
24. Verdu P, Barreiro LB, Patin E, Gessain A, Cassar O, Kidd JR, Kidd KK, Behar DM, Froment A, Heyer E, Sica L, Casanova JL, Abel L, Quintana-Murci L (2006) Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum Mol Genet 15, 2650-2658. (Pubitemid 44288693)
25. Tas SW, Klickstein LB, Barbashov SF, Nicholson-Weller A (1999) C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol 163, 5056-5063. (Pubitemid 29501274)
26. Ghiran I, Barbashov SF, Klickstein LB, Tas SW, Jensenius JC, Nicholson-Weller A (2000) Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 192, 1797-1808.
27. Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson- Weller A (1997) Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 7, 345-355. (Pubitemid 27446009)